Presented at the IASCLC 2020 North America Conference on Lung Cancer.
![[Poster] Variable Definitions of “Unresectable” Stage III NSCLC Among Lung Cancer Specialists](https://cdn.sanity.io/images/0vv8moc6/accc-cancer/3c46b90f4c71b6a7c963c766aaa68baf29cf3472-470x264.png?fit=crop&auto=format)
Presented at the IASCLC 2020 North America Conference on Lung Cancer, October 16 to October 17, 2020.
Authors
Percy P. Lee1, Leigh Boehmer2, Matthew Smeltzer3, Brendon M. Stiles4
1Department of Radiation Oncology, University of Texas MD Anderson Cancer Center; 2Association of Cancer Care Centers; 3Division of Epidemiology, Biostatistics, and Environmental Health, University of Memphis School of Public Health; 4Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital
Background
Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease that often elicits differing opinions regarding what is “unresectable”, depending upon the specialist and the treatment setting. Using survey data, we sought to characterize opinions regarding the resectability of stage III NSCLC.

In an effort to improve outcomes and deliver the highest quality of care to patients with pancreatic cancer, Duke Cancer Institute launched a multidisciplinary Pancreatic Cancer Center that prioritizes thorough surveillance of high-risk patients, stays at the forefront of clinical trials, and considers the role of comorbidities.

Electronic patient-reported outcomes (ePROs) can address limited visibility into patients' health and well-being between visits. Yet, many solutions remain generic in their workflows and mainly help capture adverse events, without helping care teams proactively manage or prevent them from worsening. Cureety offers a new kind of ePRO solution, specialized in oncology and designed to make care better quality, more efficient, and more proactive for all patients.

In the latest episode of Oncology Unscripted, hosts Deirdre Saulet and Mark Liu sit down with Andrew Ambort, DO, a palliative care consulting physician whose work in reshaping the role of palliative care across oncology helped WellSpan Health win a 2025 ACCC Innovator Award.

Patients with rare diseases and their families often feel isolated and overlooked, with many medical questions left unanswered and few people who can empathize with their condition. Rare Disease Day is observed globally each year to bring awareness for diseases and the people behind them by promoting the challenges these rare medical journeys pose for patients and caregivers.
